Skip to main content
Premium Trial:

Request an Annual Quote

Warnex Will Use LC/MS and PCR Tools in PGx Study of Gleevec for Novartis

NEW YORK (GenomeWeb News) — Warnex today said Novartis has hired it to perform bioanalytical and pharmacogenetic services for the drug maker’s leukemia and intestinal tumors program.

Warnex said its Bioanalytical Services division will use its liquid chromatography and mass spec technologies to test blood levels of Novartis’ drug Gleevec to “help identify non-adherence or suboptimal dosing.”

Warnex also will perform PCR-based diagnostic tests to determine if patients have chromosomal abnormalities.

Financial terms of the agreement were not released.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.